Order Now: brent@sdlifesciences.com
C32 Polyclonal Antibody |
JOT-AP01045-100ul |
Jotbody |
100ul |
EUR 220 |
|
Description: Human |
C32 Polyclonal Antibody |
JOT-AP01045-50ul |
Jotbody |
50ul |
EUR 144 |
|
Description: Human |
C32 Polyclonal Antibody |
E20-75730 |
EnoGene |
100ug |
EUR 225 |
Description: Available in various conjugation types. |
C32 Polyclonal Antibody |
E44H07172 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
C32 Polyclonal Antibody |
MBS2549214-002mL |
MyBiosource |
0.02mL |
EUR 140 |
C32 Polyclonal Antibody |
MBS2549214-006mL |
MyBiosource |
0.06mL |
EUR 180 |
C32 Polyclonal Antibody |
MBS2549214-012mL |
MyBiosource |
0.12mL |
EUR 260 |
C32 Polyclonal Antibody |
MBS2549214-02mL |
MyBiosource |
0.2mL |
EUR 405 |
C32 Polyclonal Antibody |
MBS8526711-01mg |
MyBiosource |
0.1mg |
EUR 305 |
C32 Polyclonal Antibody |
MBS8526711-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
C32 Polyclonal Antibody |
MBS8526711-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
C32 Polyclonal Antibody |
MBS8526711-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
C32 Polyclonal Antibody |
MBS8526711-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
C32 Polyclonal Antibody |
MBS9246346-01mL |
MyBiosource |
0.1mL |
EUR 415 |
C32 Polyclonal Antibody |
MBS9246346-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1841 |
C32 Polyclonal Antibody |
UB-GEN-15503 |
UpingBio |
100 ul |
EUR 200 |
1C04 Rabbit Polyclonal Antibody |
BT-AP00058-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: HLA-C belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide| exons 2 and 3 encode the alpha1 and alpha2 domain| which both bind the peptide| exon 4 encodes the alpha3 domain| exon 5 encodes the transmembrane region| and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Over one hundred HLA-C alleles have been described |
1C04 Rabbit Polyclonal Antibody |
BT-AP00058-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: HLA-C belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide| exons 2 and 3 encode the alpha1 and alpha2 domain| which both bind the peptide| exon 4 encodes the alpha3 domain| exon 5 encodes the transmembrane region| and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Over one hundred HLA-C alleles have been described |
1C04 Rabbit Polyclonal Antibody |
BT-AP00058-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: HLA-C belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide| exons 2 and 3 encode the alpha1 and alpha2 domain| which both bind the peptide| exon 4 encodes the alpha3 domain| exon 5 encodes the transmembrane region| and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. Over one hundred HLA-C alleles have been described |
1C04 Rabbit Polyclonal Antibody |
JOT-AP00058-100ul |
Jotbody |
100ul |
EUR 220 |
|
Description: Human, Rat, Mouse |
1C04 Rabbit Polyclonal Antibody |
JOT-AP00058-50ul |
Jotbody |
50ul |
EUR 144 |
|
Description: Human, Rat, Mouse |
C163A Rabbit Polyclonal Antibody |
BT-AP00915-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00915-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00915-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00916-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00916-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
BT-AP00916-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
JOT-AP00915-100ul |
Jotbody |
100ul |
EUR 220 |
|
C163A Rabbit Polyclonal Antibody |
JOT-AP00915-50ul |
Jotbody |
50ul |
EUR 144 |
|
C163A Rabbit Polyclonal Antibody |
JOT-AP00916-100ul |
Jotbody |
100ul |
EUR 220 |
|
C163A Rabbit Polyclonal Antibody |
JOT-AP00916-50ul |
Jotbody |
50ul |
EUR 144 |
|
C144A Rabbit Polyclonal Antibody |
JOT-AP06670-100ul |
Jotbody |
100ul |
EUR 220 |
C144A Rabbit Polyclonal Antibody |
JOT-AP06670-50ul |
Jotbody |
50ul |
EUR 144 |
C170L Rabbit Polyclonal Antibody |
JOT-AP06671-100ul |
Jotbody |
100ul |
EUR 220 |
C170L Rabbit Polyclonal Antibody |
JOT-AP06671-50ul |
Jotbody |
50ul |
EUR 144 |
C109B Rabbit Polyclonal Antibody |
E10G32622 |
EnoGene |
100 μl |
EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
AR α2C Rabbit Polyclonal Antibody |
ES1691-100ul |
ELK Biotech |
100ul |
EUR 124 |
|
Description: WB, IHC, IF, ELISA |
AR α2C Rabbit Polyclonal Antibody |
ES1691-50ul |
ELK Biotech |
50ul |
EUR 74 |
|
Description: WB, IHC, IF, ELISA |
Rabbit Polyclonal Antibody PC4 Rabbit Polyclonal Antibody |
MBS9465999-005mL |
MyBiosource |
0.05mL |
EUR 300 |
Rabbit Polyclonal Antibody PC4 Rabbit Polyclonal Antibody |
MBS9465999-01mL |
MyBiosource |
0.1mL |
EUR 390 |
Rabbit Polyclonal Antibody PC4 Rabbit Polyclonal Antibody |
MBS9465999-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1610 |
Rabbit Polyclonal Antibody PC1 Rabbit Polyclonal Antibody |
MBS9465163-005mL |
MyBiosource |
0.05mL |
EUR 300 |
Rabbit Polyclonal Antibody PC1 Rabbit Polyclonal Antibody |
MBS9465163-01mL |
MyBiosource |
0.1mL |
EUR 390 |
Rabbit Polyclonal Antibody PC1 Rabbit Polyclonal Antibody |
MBS9465163-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1610 |
C99L2 Rabbit Polyclonal Antibody |
BT-AP00950-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: This gene encodes a cell-surface protein that is similar to CD99. A similar protein in mouse functions as an adhesion molecule during leukocyte extravasation. Alternate splicing results in multiple transcript variants. |
C99L2 Rabbit Polyclonal Antibody |
BT-AP00950-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: This gene encodes a cell-surface protein that is similar to CD99. A similar protein in mouse functions as an adhesion molecule during leukocyte extravasation. Alternate splicing results in multiple transcript variants. |
C99L2 Rabbit Polyclonal Antibody |
BT-AP00950-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: This gene encodes a cell-surface protein that is similar to CD99. A similar protein in mouse functions as an adhesion molecule during leukocyte extravasation. Alternate splicing results in multiple transcript variants. |
C42S2 Rabbit Polyclonal Antibody |
JOT-AP00938-100ul |
Jotbody |
100ul |
EUR 220 |
C42S2 Rabbit Polyclonal Antibody |
JOT-AP00938-50ul |
Jotbody |
50ul |
EUR 144 |
C99L2 Rabbit Polyclonal Antibody |
JOT-AP00950-100ul |
Jotbody |
100ul |
EUR 220 |
|
C99L2 Rabbit Polyclonal Antibody |
JOT-AP00950-50ul |
Jotbody |
50ul |
EUR 144 |
|